Cipla - Thread

7 views
Skip to first unread message

RAJESH DESAI

unread,
Aug 25, 2012, 3:18:52 AM8/25/12
to LONGTERMINVESTORS, DAILY REPORTS, library-of-eq...@googlegroups.com, ai...@googlegroups.com, equity-rese...@googlegroups.com, globalspeculators, STOCK BUFFS, stock...@googlegroups.com
pfa

--
CA. Rajesh Desai

CIPLA EDEL AUG 12.pdf

RAJESH DESAI

unread,
Sep 4, 2012, 1:02:12 AM9/4/12
to LONGTERMINVESTORS, DAILY REPORTS, library-of-eq...@googlegroups.com, ai...@googlegroups.com, equity-rese...@googlegroups.com, globalspeculators, STOCK BUFFS, stock...@googlegroups.com

Cipla, is planning to buy 1.3-lakh-square-feet space in Peninsula Business Park in Lower Parel.


--
CA. Rajesh Desai

RAJESH DESAI

unread,
Sep 8, 2012, 12:44:36 AM9/8/12
to LONGTERMINVESTORS, DAILY REPORTS, library-of-eq...@googlegroups.com, ai...@googlegroups.com, equity-rese...@googlegroups.com, globalspeculators, STOCK BUFFS, stock...@googlegroups.com
(Reuters) - Delhi High Court has ruled in favour of local drugmaker Cipla in a patent infringement case filed by Switzerland's Roche Holding AG over Cipla's cancer drug Erlocip, a senior executive of the company said.

The court made the ruling a week before the Supreme Court is due to begin hearing a patent plea by another Swiss drugmaker, Novartis AG , over its cancer drug Glivec. That case is expected to set a precedent for the Indian drug market, where major western companies are fighting to protect their intellectual property.

"The court judgement says we have not infringed any patent," S. Radhakrishnan, a director on Cipla's board, told Reuters late on Friday after the Delhi High Court's ruling.

Roche accuses Cipla of infringing its patent on cancer drug Tarceva, which Cipla sells under the brand name Erlocip.

Roche could not immediately be reached for comment. The company has the option to challenge the judgement in the Supreme Court.

The ruling comes nearly four years after the court rejected Roche's attempt to stop Cipla from selling Erlocip in India.

The court, however, said that Roche's patent over Tarceva is valid in India, media reports said.





--
CA. Rajesh Desai

Rajesh Desai

unread,
May 15, 2013, 12:31:29 AM5/15/13
to longterminve...@googlegroups.com, DAILY REPORTS, library-of-eq...@googlegroups.com
CIPLA : A lobby group of biotech drug companies in India has raised concerns    about the approval of Cipla's first biosimilar drug Etanercept, used for the    treatment of rheumatic disorders

--
CA. Rajesh Desai
Reply all
Reply to author
Forward
0 new messages